Clinical Trials Browser

Liver Neoplasms × pembrolizumab × 30 days × Clear all

NCT04134559 2026-02-24

Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma

Phase 2 Recruiting

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Hepatocellular, Liver Neoplasms

NCT05438420 2026-02-24

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Phase 1/2 Active not recruiting

GastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Stomach Neoplasms